PMID- 16007684
OWN - NLM
STAT- MEDLINE
DCOM- 20050929
LR  - 20161124
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 104
IP  - 5
DP  - 2005 Sep 1
TI  - Localization of the endothelin system in human diffuse astrocytomas.
PG  - 1049-57
AB  - BACKGROUND: Endothelin-1 (ET-1), a vasoconstrictor and mitogen, has recently been 
      implicated in the pathogenesis of human glioblastoma, neuroblastoma, and 
      meningioma. ET-1, formed by proteolysis of the propeptide big ET-1 by 
      endothelin-converting enzyme-1 (ECE-1), mediates its cellular actions through ETA 
      and ETB receptors. Because only immunoreactive ET-1 has been observed within 
      human astrocytic tumor cells, the authors investigated the localization of the 
      entire ET-1 system (ET-1 mRNA, ET-1, ECE-1, ETA and ETB receptors) in surgical 
      samples of human diffuse astrocytomas WHO Grade II (n = 6). METHODS: ET-1 mRNA 
      expression was elucidated by in situ reverse transcriptase polymerase chain 
      reaction (RT-PCR) using synthetic primers. Polyclonal antibodies were used to 
      localize ET-1, ECE-1, ETA and ETB receptors by immunocytochemistry. RESULTS: All 
      ET components were detected in the six tumor samples. Intense (3+) cytoplasmic 
      ET-1 mRNA labeling was observed in more than 75% of cells in all 6 astrocytomas. 
      Up to 75% of tumor cells displayed intense ET-1 and ECE-1 immunolabeling 
      distributed throughout their cytoplasm. Immunoreactive ETA and ETB receptors, 
      observed in 25% to 75% of astrocytic tumor cells, were of moderate intensity. In 
      addition, all components of the ET system were seen within endothelial cells of 
      tumor blood vessels. CONCLUSIONS: The presence of ET-1 mRNA, ECE-1, and ET-1 
      within tumor astrocytes suggests local ET synthesis and processing. The mitogenic 
      and antiapoptotic properties of ET-1, as well as the vasodilatory signaling of 
      ETB receptors, may promote tumorigenesis.
FAU - Naidoo, Vinogran
AU  - Naidoo V
AD  - Department of Pharmacology, Nelson R. Mandela School of Medicine, University of 
      KwaZulu-Natal, Durban, South Africa.
FAU - Naidoo, Strinivasen
AU  - Naidoo S
FAU - Mahabeer, Rajeshree
AU  - Mahabeer R
FAU - Raidoo, Deshandra M
AU  - Raidoo DM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Endothelin-1)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptor, Endothelin A)
RN  - 0 (Receptor, Endothelin B)
RN  - EC 3.4.23.- (Aspartic Acid Endopeptidases)
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - EC 3.4.24.71 (ECE1 protein, human)
RN  - EC 3.4.24.71 (Endothelin-Converting Enzymes)
SB  - IM
MH  - Adult
MH  - Aspartic Acid Endopeptidases/*analysis
MH  - Astrocytoma/*chemistry/etiology
MH  - Endothelin-1/*analysis/genetics/physiology
MH  - Endothelin-Converting Enzymes
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Metalloendopeptidases/*analysis
MH  - RNA, Messenger/analysis
MH  - Receptor, Endothelin A/*analysis
MH  - Receptor, Endothelin B/*analysis
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2005/07/12 09:00
MHDA- 2005/09/30 09:00
CRDT- 2005/07/12 09:00
PHST- 2005/07/12 09:00 [pubmed]
PHST- 2005/09/30 09:00 [medline]
PHST- 2005/07/12 09:00 [entrez]
AID - 10.1002/cncr.21277 [doi]
PST - ppublish
SO  - Cancer. 2005 Sep 1;104(5):1049-57. doi: 10.1002/cncr.21277.